Hong Kong Laureate Forum: Calling Outstanding Young Scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences!
14.9.2020 04:00:00 EEST | Business Wire | Press release
Open application for the inaugural Hong Kong Laureate Forum starts today and will end on 13 December 2020. We welcome undergraduates, postgraduates and PhD graduates who are aged 35 or below and studying or conducting research in Astronomy, Life Science and Medicine, Mathematical Sciences or other closely related subjects to apply for the Hong Kong Laureate Forum and become one of the 200 selected young scientists to be inspired by world-renowned Shaw Laureates. Eligible Young Scientists are welcome to complete and submit their applications via this link: https://hklaureateforum.org/en/application-form
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200913005003/en/
Open Application from 14 September to 13 December 2020 (Graphic: Business Wire)
The inaugural Hong Kong Laureate Forum will be held on 15-20 November 2021 in Hong Kong. Being Asia’s world city and a city long celebrated for its vibrancy, Hong Kong is an ideal place for such an international gathering.
During a week-long programme, there will be ample opportunities for exchanges between participating Shaw Laureates and the young scientists. Apart from plenary lectures, panel discussions and parallel group sessions conducted by Shaw Laureates and other distinguished scientists, the programme will also offer informal and cozy gatherings with plenty of chances of networking and dialogues. There will also be presentation sessions for selected young scientists to showcase their latest research ideas to spark intellectual exchanges.
Mrs DO PANG Wai Yee, Secretary-General of the Council of the Hong Kong Laureate Forum (the HKLF) said: “As of today, we have received positive response from over 20 Shaw Laureates, including several Nobel Laureates and Fields Medalist, to join our Forum.”
Professor Steven Balbus, Shaw Laureate in Astronomy 2013 remarked: “I have nothing but pleasant memories of Hong Kong and I look forward to many more. It’s a city that feels exciting and that things are working. I think the Hong Kong Laureate Forum is going to be extremely exciting and a very special program that’s going to capture the imagination of the public.”
Professor Simon White, Shaw Laureate in Astronomy 2017 said: “I think the significance of the Shaw Prize is because it makes certain aspects of science visible to a wider public. And this fuels the curiosity which leads people to do science, which pushes them to improve their capabilities. I hope the Hong Kong Laureate Forum will make young people really enthusiastic and curious about science.”
The most outstanding 200 young scientists will be selected to join the inaugural Forum by a Scientific Review Panel comprising local and non-local academics. All applicants, either successful or not, will receive email notification in April 2021.
For enquiries regarding application, please contact Forum Programmes and Participants Enquiry at programme@hklaureateforum.org.
Background
The Hong Kong Laureate Forum is an annual scientific exchange event organized by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by Lee Shau Kee Foundation. The important partner of the HKLF is The Shaw Prize Foundation which organizes the annual international award The Shaw Prize.
To the Press
With this press release, we would like to extend an invitation to the Press to attend and report on the inaugural Hong Kong Laureate Forum.
Website:
https://www.hklaureateforum.org
Facebook:
https://www.facebook.com/HKLaureateForum
Twitter:
https://www.twitter.com/HKLaureateForum
Weibo:
https://www.weibo.com/hklaureateforum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200913005003/en/
Contact information
Forum Programmes and Participants Enquiry
Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom